Hee Jin Kim1,2, Seongbeom Park1,2, Hanna Cho3, Young Kyoung Jang1,2, Jin San Lee4, Hyemin Jang1,2, Yeshin Kim1,2,5, Ko Woon Kim1,2,6, Young Hoon Ryu7, Jae Yong Choi8, Seung Hwan Moon9, Michael W Weiner10, William J Jagust11, Gil D Rabinovici12, Charles DeCarli13, Chul Hyoung Lyoo3, Duk L Na1,2,14, Sang Won Seo1,2,10,15. 1. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Neuroscience Center, Samsung Medical Center, Seoul, Korea. 3. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. 4. Department of Neurology, Kyung Hee University Hospital, Seoul, Korea. 5. Department of Neurology, Kangwon National University College of Medicine, Chuncheon-si, Gangwon-do, Korea. 6. Department of Neurology, Chonbuk National University Medical School and Hospital, Jeonju, Korea. 7. Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 8. Division of RI-Convergence Research, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea. 9. Departments of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 10. Center for Imaging of Neurodegenerative Diseases, University of California, San Francisco. 11. Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley. 12. Memory and Aging Center, Department of Neurology, University of California, San Francisco. 13. Department of Neurology and Center for Neuroscience, University of California, Davis. 14. Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea. 15. Department of Clinical Research Design and Evaluation, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
Abstract
Importance: Amyloid-β (Aβ), tau, and cerebral small vessel disease (CSVD), which occasionally coexist, are the most common causes of cognitive impairments in older people. However, whether tau is observed in patients with subcortical vascular cognitive impairment (SVCI), as well as its associations with Aβ and CSVD, are not yet established. More importantly, the role of tau underlying cognitive impairments in SVCI is unknown. Objective: To investigate the extent and the role of tau in patients with SVCI using 18F-AV1451, which is a new ligand to detect neurofibrillary tangles in vivo. Design, Setting, and Participants: This cross-sectional study recruited 64 patients with SVCI from June 2015 to December 2016 at Samsung Medical Center, Seoul, Korea. The patients had significant ischemia on brain magnetic resonance imaging, defined as periventricular white matter hyperintensity at least 10 mm and deep white matter hyperintensity at least 25 mm. We excluded 3 patients with SVCI owing to segmentation error during AV1451 positron emission tomography analysis. Main Outcomes and Measures: We calculated CSVD scores based on the volumes of white matter hyperintensities, numbers of lacunes, and microbleeds using magnetic resonance imaging data. The presence of Aβ was assessed using fluorine 18-labeled (18F) florbetaben positron emission tomography. Tau was measured using 18F-AV1451 positron emission tomography. We determined the spreading order of tau by sorting the regional frequencies of cortical involvement. We evaluated the complex associations between Aβ, CSVD, AV1451 uptake, and cognition in patients with SVCI. Results: Of the 61 patients with SVCI, 44 (72.1%) were women and the mean (SD) age was 78.7 (6.3) years. Patients with SVCI, especially patients with Aβ-negative SVCI, showed higher AV1451 uptake in the inferior temporal areas compared with normal control individuals. In patients with SVCI, Aβ positivity and CSVD score were each independently associated with increased AV1451 uptake in the medial temporal and inferior temporal regions, respectively. Involvement frequency of AV1451 uptake in the fusiform gyrus, inferior temporal, and precuneus regions were higher than that in the parahippocampal region. In patients with SVCI, higher AV1451 uptake in the inferior temporal and medial temporal regions correlated with worse language and general cognitive function. In patients with SVCI, Aβ positivity and CSVD score each correlated with worse general cognitive function, which was completely mediated by AV1451 uptake in the entorhinal cortex and inferior temporal gyrus, respectively. Conclusions and Relevance: Our findings suggest that in SVCI, both Aβ and CSVD were independently associated with increased tau accumulation. Furthermore, tau burden played a pivotal role because it was the final common pathway for the cognitive impairment in patients with SVCI.
Importance: Amyloid-β (Aβ), tau, and cerebral small vessel disease (CSVD), which occasionally coexist, are the most common causes of cognitive impairments in older people. However, whether tau is observed in patients with subcortical vascular cognitive impairment (SVCI), as well as its associations with Aβ and CSVD, are not yet established. More importantly, the role of tau underlying cognitive impairments in SVCI is unknown. Objective: To investigate the extent and the role of tau in patients with SVCI using 18F-AV1451, which is a new ligand to detect neurofibrillary tangles in vivo. Design, Setting, and Participants: This cross-sectional study recruited 64 patients with SVCI from June 2015 to December 2016 at Samsung Medical Center, Seoul, Korea. The patients had significant ischemia on brain magnetic resonance imaging, defined as periventricular white matter hyperintensity at least 10 mm and deep white matter hyperintensity at least 25 mm. We excluded 3 patients with SVCI owing to segmentation error during AV1451 positron emission tomography analysis. Main Outcomes and Measures: We calculated CSVD scores based on the volumes of white matter hyperintensities, numbers of lacunes, and microbleeds using magnetic resonance imaging data. The presence of Aβ was assessed using fluorine 18-labeled (18F) florbetaben positron emission tomography. Tau was measured using 18F-AV1451 positron emission tomography. We determined the spreading order of tau by sorting the regional frequencies of cortical involvement. We evaluated the complex associations between Aβ, CSVD, AV1451 uptake, and cognition in patients with SVCI. Results: Of the 61 patients with SVCI, 44 (72.1%) were women and the mean (SD) age was 78.7 (6.3) years. Patients with SVCI, especially patients with Aβ-negative SVCI, showed higher AV1451 uptake in the inferior temporal areas compared with normal control individuals. In patients with SVCI, Aβ positivity and CSVD score were each independently associated with increased AV1451 uptake in the medial temporal and inferior temporal regions, respectively. Involvement frequency of AV1451 uptake in the fusiform gyrus, inferior temporal, and precuneus regions were higher than that in the parahippocampal region. In patients with SVCI, higher AV1451 uptake in the inferior temporal and medial temporal regions correlated with worse language and general cognitive function. In patients with SVCI, Aβ positivity and CSVD score each correlated with worse general cognitive function, which was completely mediated by AV1451 uptake in the entorhinal cortex and inferior temporal gyrus, respectively. Conclusions and Relevance: Our findings suggest that in SVCI, both Aβ and CSVD were independently associated with increased tau accumulation. Furthermore, tau burden played a pivotal role because it was the final common pathway for the cognitive impairment in patients with SVCI.
Authors: Anika M S Hartz; Björn Bauer; Emma L B Soldner; Andrea Wolf; Sandra Boy; Roland Backhaus; Ivan Mihaljevic; Ulrich Bogdahn; Hans H Klünemann; Gerhard Schuierer; Felix Schlachetzki Journal: Stroke Date: 2011-11-23 Impact factor: 7.914
Authors: Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo Journal: Ann Neurol Date: 2016-07-08 Impact factor: 10.422
Authors: Hyun-Jung Ahn; Juhee Chin; Aram Park; Byung Hwa Lee; Mee Kyung Suh; Sang Won Seo; Duk L Na Journal: J Korean Med Sci Date: 2010-06-17 Impact factor: 2.153
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: Stephen N Gomperts; Joseph J Locascio; Sara J Makaretz; Aaron Schultz; Christina Caso; Neil Vasdev; Reisa Sperling; John H Growdon; Bradford C Dickerson; Keith Johnson Journal: JAMA Neurol Date: 2016-11-01 Impact factor: 18.302
Authors: Margaret M Esiri; Catharine Joachim; Carolyn Sloan; Sharon Christie; Grzegorz Agacinski; Leslie R Bridges; Gordon K Wilcock; A David Smith Journal: Alzheimer Dis Assoc Disord Date: 2014 Jan-Mar Impact factor: 2.703
Authors: Nicolai Franzmeier; Anna Rubinski; Julia Neitzel; Yeshin Kim; Alexander Damm; Duk L Na; Hee Jin Kim; Chul Hyoung Lyoo; Hana Cho; Sofia Finsterwalder; Marco Duering; Sang Won Seo; Michael Ewers Journal: Brain Date: 2019-04-01 Impact factor: 13.501
Authors: Saffire H Krance; Hugo Cogo-Moreira; Jennifer S Rabin; Sandra E Black; Walter Swardfager Journal: J Neurosci Date: 2019-07-26 Impact factor: 6.167
Authors: Vladimir Hachinski; Karl Einhäupl; Detlev Ganten; Suvarna Alladi; Carol Brayne; Blossom C M Stephan; Melanie D Sweeney; Berislav Zlokovic; Yasser Iturria-Medina; Costantino Iadecola; Nozomi Nishimura; Chris B Schaffer; Shawn N Whitehead; Sandra E Black; Leif Østergaard; Joanna Wardlaw; Steven Greenberg; Leif Friberg; Bo Norrving; Brian Rowe; Yves Joanette; Werner Hacke; Lewis Kuller; Martin Dichgans; Matthias Endres; Zaven S Khachaturian Journal: Alzheimers Dement Date: 2019-07 Impact factor: 21.566
Authors: Jennifer S Rabin; Hyun-Sik Yang; Aaron P Schultz; Bernard J Hanseeuw; Trey Hedden; Anand Viswanathan; Jennifer R Gatchel; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Vaishnavi Rao; Rachel F Buckley; Wai-Ying Wendy Yau; Dylan R Kirn; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal Journal: Ann Neurol Date: 2019-01-07 Impact factor: 10.422
Authors: Hyemin Jang; Hee Jin Kim; Seongbeom Park; Yu Hyun Park; Yeongsim Choe; Hanna Cho; Chul Hyoung Lyoo; Uicheul Yoon; Jin San Lee; Yeshin Kim; Seung Joo Kim; Jun Pyo Kim; Young Hee Jung; Young Hoon Ryu; Jae Yong Choi; Seung Hwan Moon; Joon-Kyung Seong; Charles DeCarli; Michael W Weiner; Samuel N Lockhart; Soo Hyun Cho; Duk L Na; Sang Won Seo Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-31 Impact factor: 9.236
Authors: Elizabeth E Moore; Timothy J Hohman; Faizan S Badami; Kimberly R Pechman; Katie E Osborn; Lealani Mae Y Acosta; Susan P Bell; Michelle A Babicz; Katherine A Gifford; Adam W Anderson; Lee E Goldstein; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson Journal: Neurobiol Aging Date: 2018-06-28 Impact factor: 4.673
Authors: Xi Chen; Kaitlin E Cassady; Jenna N Adams; Theresa M Harrison; Suzanne L Baker; William J Jagust Journal: J Neurosci Date: 2020-11-20 Impact factor: 6.167
Authors: Giuseppe Faraco; Karin Hochrainer; Steven G Segarra; Samantha Schaeffer; Monica M Santisteban; Ajay Menon; Hong Jiang; David M Holtzman; Josef Anrather; Costantino Iadecola Journal: Nature Date: 2019-10-23 Impact factor: 49.962
Authors: Jin San Lee; Hyejoo Lee; Seongbeom Park; Yeongsim Choe; Yu Hyun Park; Bo Kyoung Cheon; Alice Hahn; Rik Ossenkoppele; Hee Jin Kim; Seonwoo Kim; Heejin Yoo; Hyemin Jang; Soo Hyun Cho; Seung Joo Kim; Jun Pyo Kim; Young Hee Jung; Key-Chung Park; Charles DeCarli; Michael W Weiner; Duk L Na; Sang Won Seo Journal: Neurology Date: 2020-09-14 Impact factor: 9.910